Patient and surgical factors that affect the development of velopharyngeal insufficiency.

J Plast Reconstr Aesthet Surg

Associate Professor, Division of Plastic Surgery, Department of Surgery, Western University, London, ON, Canada. Electronic address:

Published: October 2022

Velopharyngeal insufficiency (VPI) is a complication that occurs following cleft palate (CP) repair, and the patient/surgical factors that contribute to the development of VPI have not been completely described. The objectives of this study were to identify patient and surgical factors that may increase the risk of development of VPI and to identify whether there are any factors that predispose patients to the development of VPI that requires surgery versus VPI that resolves with non-operative management. Data was prospectively collected for all non-syndromic patients with a CP undergoing primary CP repair by a single surgeon between 2002 and 2018. Patient factors were recorded from patient charts, and anatomic measurements were recorded by the primary surgeon at the time of palate repair. The rates of VPI requiring surgery were compared between (1) patients with cleft lip/palate versus isolated CP, (2) patient gender, (3) unilateral or bilateral cleft, (4) complete or incomplete cleft, (5) the type of primary palatoplasty performed, and (6) the presence of palatal fistula. Data were analyzed retrospectively using a combination of Chi-square tests, t-tests, and one-way ANOVA. Overall, 229 patients were identified in this study, and the total rate of VPI was identified as 30.1%. The risk of VPI development was associated with bilateral cleft lip/palate (p = 0.01), increased pre-operative cleft width (p = 0.03), and von Langenbeck palatoplasty (p<0.01). No factors were found to be associated with operative versus non-operative VPI. Moving forward, at-risk patients should be identified early and monitored closely for the development of VPI.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjps.2022.06.036DOI Listing

Publication Analysis

Top Keywords

development vpi
12
patient surgical
8
surgical factors
8
velopharyngeal insufficiency
8
vpi
8
palate repair
8
cleft lip/palate
8
bilateral cleft
8
cleft
6
patient
5

Similar Publications

Background: Pharmacological vitamin C (Vit-C), or high-dose Vit-C has recently gained attention as a potential cancer therapeutic. However, the anticancer activity of Vit-C has not been investigated in realistic 3D models of human cancers, especially with respect to breast cancer (BC), and its potential benefits remain under debate. Herein, we investigate the activity and mechanism of action of pharmacological Vit-C on two BC tumor spheroids.

View Article and Find Full Text PDF

VPI-MD: a multi-omics database for Verticillium-plant interaction.

Plant Biotechnol J

January 2025

Key Laboratory of Oasis Town and Mountain-Basin System Ecology of Bingtuan, College of Life Sciences, Shihezi University, Shihezi, China.

View Article and Find Full Text PDF

Objectives: While the target of growth of very preterm infants (VPIs) during Neonatal Intensive care unit (NICU) admission is still controversial, the most accepted objective is that they should follow their intrauterine trajectory in terms of growth and body composition (BC). BC is difficult to measure in clinical daily routine but proxies like body ratios and skinfolds have been used. Prenatal and postnatal factors can influence the growth and BC of VPIs in the NICU.

View Article and Find Full Text PDF
Article Synopsis
  • Moringa oleifera has been traditionally used in Africa and Asia for its medicinal properties and this study explores its potential anti-leukemia effects through its leaf extracts.
  • The research involved treating leukemia cells with different concentrations of aqueous and ethanolic extracts and measuring cell viability, apoptosis, and gene expression.
  • Results indicated that these extracts were more effective on leukemia cells compared to healthy cells, highlighting the potential for Moringa extracts to be developed as a novel treatment for leukemia.
View Article and Find Full Text PDF

FOXM1 is the "Achilles' heel" of cancers and hence the potential therapeutic target for anticancer drug discovery. In this work, we selected high affinity peptides against the protein of human DNA binding domain of FOXM1 (FOXM1-DBD) from the disulfide-constrained, phage displayed random cyclic heptapeptide library Ph.D.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!